Regulation of human immunodeficiency virus (HIV) gene expression is dependent on specific regulatory regions in the long terminal repeat. These regions include the enhancer, SP1, "TATA," and trans-activating (TAR) regions. In addition, viral regulatory proteins such as tat and rev are important in regulating HIV gene expression. The mechanism of tat activation remains the subject of investigation, but effects at both transcriptional and posttranscriptional levels seem likely. Previous mutagenesis of the tat protein revealed that the amino terminus, the cysteine-rich domain, and the basic domain were all required for complete tat activation. Mutants of other viral trans-acting regulatory proteins, including ElA, tax, and VM65, have been identified that were capable of antagonizing the activity of their corresponding wild-type proteins. We wished to determine whether mutants of the tat protein could be identified that exhibited a similar phenotype.
the activity of their corresponding wild-type proteins. We wished to determine whether mutants of the tat protein could be identified that exhibited a similar phenotype. One mutant (Atat) that truncated the basic domain of tat resulted in a transdominant phenotype inhibiting tat-induced gene expression of the HIV long terminal repeat but not other viral promoters. This mutant exhibited its maximal phenotype in cotransfection experiments when present in an 8-to 30-fold molar excess over the wild-type tat gene. Trans-activation of the HIV long terminal repeat by Atat was very defective at the DNA concentrations used in these experiments. RNase protection analysis indicated that this mutant decreased tat-induced steady-state mRNA levels of the HIV long terminal repeat. Second-site mutations of the Atat gene in either the amino terminus or cysteine region eliminated the transdominant phenotype. In contrast to tat, which was localized predominantly to the nucleolus, Atat was present in both the nucleus and cytoplasm, suggesting that it may inhibit tat function by preventing nucleolar localization. Transdominant mutants of tat may have a role in potentially inhibiting HIV gene expression.
Regulation of gene expression of the human immunodeficiency virus (HIV), the causative agent of AIDS (1) (2) (3) , is dependent on specific regulatory regions in the long terminal repeat (LTR). These regions include multiple enhancer elements, the SPi, the "TATA," and the trans-activating region (TAR) (4) (5) (6) (7) (8) (9) (10) . In addition, viral proteins such as tat (11) (12) (13) (14) and rev (15, 16) are important in regulating viral gene expression. However, the mechanism by which these viral proteins activate HIV gene expression remains open to question.
tat is an 86-amino acid nuclear protein that is required for efficient viral gene expression (17) . The tat gene is capable of activating the HIV LTR fused to reporter genes such as chloramphenicol acetyltransferase (CAT) from 40-to 300-fold (11) (12) (13) (14) . This increase in gene expression is accompanied by increases in steady-state RNA levels (18, 19) , though effects on translation have also been reported (20, 21) . tat has been demonstrated to increase transcription in nuclear runon experiments with the HIV LTR (22) . Other studies using microinjection Xenopus oocytes demonstrated that tat was able to increase gene expression of the HIV LTR mRNA when both were injected into the nucleus, suggesting that tat acted at posttranscriptional levels (23) . The relative contribution of tat at both the transcriptional and posttranscriptional levels remains the subject of intense investigation.
The TAR extending from positions -17 to +80 in the HIV LTR is required for tat activation (7, 8, 11, (24) (25) (26) (27) . This element forms a stable stem-loop RNA structure. The maintenance of this stem-loop structure is required for tat activation (7, 8, 24, 25, 27) . Both cellular proteins and tat itself bind to TAR RNA (28, 29) . The significance of this binding has not yet been determined. In addition, TAR DNA also serves as binding sites for cellular proteins such as untranslated binding protein (UBP) 1 and 2, which may play a role in tat activation (8, 9, 30) .
Mutagenesis of the tat protein indicated that multiple domains, including the amino terminus, the cysteine-rich region, and the basic domain, are required for complete tat activation (31) (32) (33) (34) . Both zinc and cadmium bind to the cysteine-rich moiety, and this binding is associated with metal-linked dimers (35) . Mutation of the cysteine moieties results in HIV mutants that are severely defective in gene expression and growth (34) . The basic domain is required for nuclear (32, 33) and likely nucleolar localization of tat (17) , though it may also play a role in either DNA or RNA binding. The role of the amino terminus for tat function is not known.
Mutants of a number of other viral trans-activator proteins such as ElA (36) , tax (37) , and VM65 (38) have been identified that inhibit the promoter activation of their wildtype proteins. These so-called transdominant mutants may play a role in creating cell lines "immune" to subsequent viral infection (38, 39 (31) (32) (33) (34) . These include the amino terminus, the cysteine-rich domain containing four repeats of Cys-Xaa-Xaa-Cys, and the basic domain, which contains eight basic amino acids (lysine and arginine). A schematic of mutants used in this study is shown in Fig. 1 . Each of these mutants was severely defective in activation of the HIV LTR compared to wild-type tat as reported (31) . Mutants (Fig. 2A) . Other mutants had no detectable effect on the level of tat activation.
To determine if second-site mutations introduced into the Atat construct altered the transdominant phenotype, additional mutations were placed into Atat and then assayed for their effects on antagonism of tat activation of the HIV LTR-CAT construct. Mutations of each ofthe three cysteine residues, individually or combined, or a mutation in the amino terminus were inserted into the Atat construct. As shown in Fig. 2B , lane 1, the Atat mutation inhibited tat activation of the HIV LTR when present in an 8-fold molar excess over tat. However, the introduction of other secondsite mutations eliminated this antagonism of tat activation (Fig. 2B, lanes 2-5) . The level of the HIV LTR-CAT construct in the presence of tat is also shown (Fig. 2B, lane 6) . This suggests that the conformation of the Atat protein was critical for the maintenance of the transdominant phenotype.
Transdominant Repression of tat Function. Titration of wild-type tat gene with either Atat or another mutant, Acys, which eliminated the three critical cysteine residues in the tat gene (illustrated in Fig. 1 ), was performed to determine the range over which these mutants antagonized wild-type tat activation. As shown in Fig. 3A, lanes 4-6, (Fig. 3A, lanes 7-9) . However, transfection of either a 2-, 8-, or 30-fold excess of Atat resulted in marked antagonism of tat activation of the HIV LTR (Fig. 3A, lanes 1-3) . The HIV LTR-CAT plasmid in the absence of tat is also shown (Fig. 3A, lanes 10-12) . This antagonism by Atat when present in an 8-or 30-fold molar excess over wild-type tat resulted in severe decreases in CAT activity in four independent experiments.
The Atat mutant was markedly defective (20-to 40-fold in three experiments) in activating the HIV LTR-CAT plasmid as compared to wild-type tat (Fig. 3B) . However, at higher DNA concentrations (5-10 ,g), low-level activation of the HIV LTR was noted (data not shown). Atat did not decrease gene expression from the RSV-CAT plasmid (Fig. 3C ) or other viral promoters tested. Thus, Atat was very defective for activation of the HIV LTR and it appeared to specifically antagonize tat activation of the HIV LTR.
Transdominant Inhibition of tat-Induced Steady-State RNA Levels. To determine whether Atat inhibition resulted in a decrease in tat-induced steady-state RNA levels of the HIV A B AM LTR, RNase protection was performed on RNA prepared after transfection of HIV LTR-CAT and wild-type tat, ,3-globin, or wild-type tat plus an 8-fold excess of either Atat or Acys. Transfections were normalized for the levels of luciferase activity by inclusion of a thymidine kinaseluciferase construct in each transfection mixture (data not shown). As shown in Fig. 4A , the presence of Atat and tat resulted in a marked decrease in the 150-bp RNase protected CAT mRNA band as compared to the presence of Acys and tat (Fig. 4, lanes 1 and 2) . The level ofHIV LTR-CAT mRNA in the presence of either f3-globin or tat alone are also indicated (Fig. 4, lanes 3 and 4) . The intensity of the 142-bp RNase-protected tat mRNA band was roughly equivalent in the presence of tat and either Atat or Acys (Fig. 4, lanes 1 and  2) . These results indicated that Atat decreased the amount of tat-induced steady-state mRNA from the HIV LTR.
Nucleolar Localization ofAtat Is Altered. The tat protein has been shown by immunofluorescence to be localized to the nucleus with the majority of the protein present in the nucleolus (17, 33) . To compare the cellular localization of tat and Atat, these constructs were individually transfected into HeLa cells and localized by immunofluorescence with tat antibody. As shown in Fig. SB , tat was primarily localized to the nucleolus. However, Atat was localized to both the nucleus and the cytoplasm with little detectable accumulation in the nucleolus (Fig. 5D ). This pattern of staining was not seen with preimmune serum, indicating the specificity of the tat antibody (data not shown). Thus, a potential mechanism of Atat antagonism of tat activation may be inhibition of tat localization to the nucleolus.
DISCUSSION
The results presented herein demonstrate that a truncation of the tat gene, Atat, was capable of antagonizing wild-type tat activation of the HIV LTR. This antagonism was maximal when Atat was present in an 8-to 30-fold molar excess over the wild-type tat gene in transfection experiments. This effect was due to an inhibition of the tat-induced steady-state RNA levels from the HIV LTR-CAT construct. Second-site mutations of the Atat construct resulted in the loss of the transdominant phenotype. This inhibition was specific for the HIV LTR and not for other promoters. The mechanism of this transdominant phenotype is not known. However, the requirement for the structural integrity of the Atat protein and the previous demonstration of the presence of metal-linked dimers of tat would be consistent with a model that tat and Atat may form heterodimers with a defective activation phenotype. Potential inhibition in tat localization to the nucleolus or defective interaction with HIV LTR DNA, RNA, or cellular transcription factors remain other possible explanations for this transdominant phenotype. A number of previous tat mutants in the basic domain have been constructed (32, 33) . These studies indicate that point mutations in the basic domain do not result in large decreases in tat activation. However, mutations that either truncated the tat gene in the basic domain or substituted multiple amino acids in this domain result in marked decreases in tat activation. Immunofluorescence experiments have indicated that the basic domain functioned in the nuclear and likely the nucleolar localization of tat (17, 32, 33) , though this domain may also play a role in the in vivo stability of the tat protein (32) . However, our immunofluorescence studies indicate that Atat protein was present in roughly equivalent quantities as that of tat after transfection of these constructs. The amino acid residues GRKKR in the basic domain of tat have been shown to be required for nuclear localization, as have similar sequences in other cellular proteins (42, 43 can be used to create cell lines that are "immune" to viral infection (39) . Transdominant mutations have been described for other HIV proteins including rev (44) and gag (45) . These mutant proteins were capable of antagonizing the growth of HIV. Previous studies of the tat protein using chemically synthesized peptides have been reported (46) (47) (48) . One group reported that a 50-amino acid tat peptide between amino acids 37 and 86, which eliminated the cysteine-rich domain, had wild-type trans-activation properties (46) . Furthermore, peptides containing amino acids 37-62 and substitutions between amino acids 40 and 47 were reported to have transdominant phenotypes (47) . However, another study using similar peptides failed to confirm either the activation by these tat peptides or their transdominant phenotype (48) 
